Bone Biologics Co. (OTC:BBLG – Get Rating)’s stock price traded down 2.8% on Thursday . The stock traded as low as $1.18 and last traded at $1.40. 13,499 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 779,648 shares. The stock had previously closed at $1.44.
The stock’s 50-day simple moving average is $1.60 and its 200 day simple moving average is $2.31.
An institutional investor recently bought a new position in Bone Biologics stock. Jane Street Group LLC bought a new stake in Bone Biologics Co. (OTC:BBLG – Get Rating) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,464 shares of the company’s stock, valued at approximately $37,000. Jane Street Group LLC owned 0.13% of Bone Biologics as of its most recent filing with the Securities and Exchange Commission (SEC).
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration.
- Get a free copy of the StockNews.com research report on Bone Biologics (BBLG)
- Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
- MarketBeat: Week in Review 6/27 – 7/1
- Accolade Moves Higher But Growth Is Slowing
- ZIM Integrated Shipping Services (ZIM): Don’t Miss This Dividend
- RH Gives Good Reason To Get Defensive
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.